A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

NCT07677514 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: H021 Enteric-coated Tablets Low-dose Group
DRUG: H021 Enteric-coated Tablets High-dose Group
DRUG: Placebo Group

Sponsor

Jiangsu Carephar Pharmaceutical Co., Ltd.